Reflecting a rotation into defensive health care stocks, and responding to positive clinical trial news, vaccine producer Moderna (MRNA) jumped 30 spots in the SIA S&P 500 Index Report yesterday to 13th place. The shares have been climbing back up the rankings since October and since they returned to the Green Favored Zone in early November, they have returned 27.3%.
Menu